Cargando…

adipoSIGHT in Therapeutic Response: Consequences in Osteosarcoma Treatment

Chemotherapeutic resistance is a major problem in effective cancer treatment. Cancer cells engage various cells or mechanisms to resist anti-cancer therapeutics, which results in metastasis and the recurrence of disease. Considering the cellular heterogeneity of cancer stroma, the involvement of ste...

Descripción completa

Detalles Bibliográficos
Autores principales: Kundu, Banani, Brancato, Virginia, Oliveira, Joaquim, Correlo, Vitor M., Reis, Rui L., Kundu, Subhas C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229256/
https://www.ncbi.nlm.nih.gov/pubmed/34200614
http://dx.doi.org/10.3390/bioengineering8060083
_version_ 1783712934711525376
author Kundu, Banani
Brancato, Virginia
Oliveira, Joaquim
Correlo, Vitor M.
Reis, Rui L.
Kundu, Subhas C.
author_facet Kundu, Banani
Brancato, Virginia
Oliveira, Joaquim
Correlo, Vitor M.
Reis, Rui L.
Kundu, Subhas C.
author_sort Kundu, Banani
collection PubMed
description Chemotherapeutic resistance is a major problem in effective cancer treatment. Cancer cells engage various cells or mechanisms to resist anti-cancer therapeutics, which results in metastasis and the recurrence of disease. Considering the cellular heterogeneity of cancer stroma, the involvement of stem cells is reported to affect the proliferation and metastasis of osteosarcoma. Hence, the duo (osteosarcoma: Saos 2 and human adipose-derived stem cells: ASCs) is co-cultured in present study to investigate the therapeutic response using a nonadherent, concave surface. Staining with a cell tracker allows real-time microscopic monitoring of the cell arrangement within the sphere. Cell–cell interaction is investigated by means of E-cadherin expression. Comparatively high expression of E-cadherin and compact organization is observed in heterotypic tumorspheres (Saos 2–ASCs) compared to homotypic ones (ASCs), limiting the infiltration of chemotherapeutic compound doxorubicin into the heterotypic tumorsphere, which in turn protects cells from the toxic effect of the chemotherapeutic. In addition, genes known to be associated with drug resistance, such as SOX2, OCT4, and CD44 are overexpressed in heterotypic tumorspheres post-chemotherapy, indicating that the duo collectively repels the effect of doxorubicin. The interaction between ASCs and Saos 2 in the present study points toward the growing oncological risk of using ASC-based regenerative therapy in cancer patients and warrants further investigation.
format Online
Article
Text
id pubmed-8229256
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82292562021-06-26 adipoSIGHT in Therapeutic Response: Consequences in Osteosarcoma Treatment Kundu, Banani Brancato, Virginia Oliveira, Joaquim Correlo, Vitor M. Reis, Rui L. Kundu, Subhas C. Bioengineering (Basel) Article Chemotherapeutic resistance is a major problem in effective cancer treatment. Cancer cells engage various cells or mechanisms to resist anti-cancer therapeutics, which results in metastasis and the recurrence of disease. Considering the cellular heterogeneity of cancer stroma, the involvement of stem cells is reported to affect the proliferation and metastasis of osteosarcoma. Hence, the duo (osteosarcoma: Saos 2 and human adipose-derived stem cells: ASCs) is co-cultured in present study to investigate the therapeutic response using a nonadherent, concave surface. Staining with a cell tracker allows real-time microscopic monitoring of the cell arrangement within the sphere. Cell–cell interaction is investigated by means of E-cadherin expression. Comparatively high expression of E-cadherin and compact organization is observed in heterotypic tumorspheres (Saos 2–ASCs) compared to homotypic ones (ASCs), limiting the infiltration of chemotherapeutic compound doxorubicin into the heterotypic tumorsphere, which in turn protects cells from the toxic effect of the chemotherapeutic. In addition, genes known to be associated with drug resistance, such as SOX2, OCT4, and CD44 are overexpressed in heterotypic tumorspheres post-chemotherapy, indicating that the duo collectively repels the effect of doxorubicin. The interaction between ASCs and Saos 2 in the present study points toward the growing oncological risk of using ASC-based regenerative therapy in cancer patients and warrants further investigation. MDPI 2021-06-10 /pmc/articles/PMC8229256/ /pubmed/34200614 http://dx.doi.org/10.3390/bioengineering8060083 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kundu, Banani
Brancato, Virginia
Oliveira, Joaquim
Correlo, Vitor M.
Reis, Rui L.
Kundu, Subhas C.
adipoSIGHT in Therapeutic Response: Consequences in Osteosarcoma Treatment
title adipoSIGHT in Therapeutic Response: Consequences in Osteosarcoma Treatment
title_full adipoSIGHT in Therapeutic Response: Consequences in Osteosarcoma Treatment
title_fullStr adipoSIGHT in Therapeutic Response: Consequences in Osteosarcoma Treatment
title_full_unstemmed adipoSIGHT in Therapeutic Response: Consequences in Osteosarcoma Treatment
title_short adipoSIGHT in Therapeutic Response: Consequences in Osteosarcoma Treatment
title_sort adiposight in therapeutic response: consequences in osteosarcoma treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229256/
https://www.ncbi.nlm.nih.gov/pubmed/34200614
http://dx.doi.org/10.3390/bioengineering8060083
work_keys_str_mv AT kundubanani adiposightintherapeuticresponseconsequencesinosteosarcomatreatment
AT brancatovirginia adiposightintherapeuticresponseconsequencesinosteosarcomatreatment
AT oliveirajoaquim adiposightintherapeuticresponseconsequencesinosteosarcomatreatment
AT correlovitorm adiposightintherapeuticresponseconsequencesinosteosarcomatreatment
AT reisruil adiposightintherapeuticresponseconsequencesinosteosarcomatreatment
AT kundusubhasc adiposightintherapeuticresponseconsequencesinosteosarcomatreatment